Pedro Alonso, Talking About the RTS,S Vaccine
Areas of Action: Malaria Elimination
Pedro Alonso, the Director of ISGlobal, talks about the results of a Phase 3 trial which has demonstrated that the RTS,S malaria vaccine candidate reduces the risk of contracting the disease by 50% in African children aged 5 to 17 months.